TITLE

Clinical Outcomes of Elite Controllers, Viremic Controllers, and Long-Term Nonprogressors in the US Department of Defense HIV Natural History Study

AUTHOR(S)
Okulicz, Jason F.; Marconi, Vincent C.; Landrum, Michael L.; Wegner, Scott; Weintrob, Amy; Ganesan, Anuradha; Hale, Braden; Crum-Cianflone, Nancy; Delmar, Judith; Barthel, Vincent; Quinnan, Gerald; Agan, Brian K.; Dolan, Matthew J.
PUB. DATE
December 2009
SOURCE
Journal of Infectious Diseases;12/1/2009, Vol. 200 Issue 11, p1714
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Durable control of human immunodeficiency virus (HIV) replication and lack of disease progression in the absence of antiretroviral therapy were studied in a military cohort of 4586 subjects. We examined groups of elite controllers (ie, subjects with plasma HIV RNA levels of <50 copies/mL; prevalence, 0.55% [95% confidence interval {CI}, 0.35%-0.80%]), viremic controllers (ie, subjects with plasma HIV RNA levels of 50-2000 copies/ mL; prevalence, 3.34% [95% CI, 2.83%-3.91%]), and subjects with a lack of disease progression (ie, long-term nonprogressors [LTNPs]) through 7 years of follow-up (LTNP7s; prevalence, 3.32% [95% CI, 2.70%-4.01%]) or 10 years of follow-up (LTNP10s; prevalence, 2.04% [95% CI, 1.52%-2.68%]). For elite and viremic controllers, spontaneous virologic control was established early and was typically observed when the initial viral load measurement was obtained within 1 year of estimated seroconversion. Elite controllers had favorable time to development of AIDS ( ), a P=.048 CD4 cell count of 350 cells/μL (P=.009), and more-stable CD4 cell trends, compared with viremic controllers. LTNPs defined by 10-year versus 7-year criteria had a longer survival time (P=.001), even after adjustment for differing periods of invulnerability (P=.042). Definitions of controllers and LTNPs describe distinct populations whose differing clinical outcomes improve with the stringency of criteria, underscoring the need for comparability between study populations.
ACCESSION #
45566196

 

Related Articles

  • The Setpoint Study (ACTG A5217): Effect of Immediate Versus Deferred Antiretroviral Therapy on Virologic Set Point in Recently HIV-1-Infected Individuals. Hogan, Christine M.; DeGruttola, Victor; Sun, Xin; Fiscus, Susan A.; Rio, Carlos Del; Hare, C. Bradley; Markowitz, Martin; Connick, Elizabeth; Macatangay, Bernard; Tashima, Karen T.; Kallungal, Beatrice; Camp, Rob; Morton, Tia; Daar, Eric S.; Little, Susan // Journal of Infectious Diseases;1/1/2012, Vol. 205 Issue 1, p87 

    Background. The benefits of antiretroviral therapy during early human immunodeficiency virus type 1 (HIV-1) infection remain unproved. Methods. A5217 study team randomized patients within 6 months of HIV-1 seroconversion to receive either 36 weeks of antiretrovirals (immediate treatment [IT]) or...

  • Human immunodeficiency virus type-1 episomal cDNA in semen. Chong Xu; Politch, Joseph A.; Mayer, Kenneth H.; Anderson, Deborah J. // AIDS Research & Therapy;2005, Vol. 2, p9 

    Background: Episomal 2-long terminal repeat (LTR) HIV-1 cDNA, a by-product of HIV-1 infection, is used in clinical trials as a marker for ongoing viral replication. It would be useful to employ 2-LTR cDNA to monitor cryptic HIV-1 infection in the genital tract of men on antiretroviral therapy...

  • Pretreatment Levels of Soluble Cellular Receptors and Interleukin-6 Are Associated with HIV Disease Progression in Subjects Treated with Highly Active Antiretroviral Therapy. Kalayjian, Robert C.; Machekano, Rhoderick N.; Rizk, Nesrine; Robbins, Gregory K.; Gandhi, Rajesh T.; Rodriguez, Benigno A.; Pollard, Richard B.; Lederman, Michael M.; Landay, Alan // Journal of Infectious Diseases;6/15/2010, Vol. 201 Issue 12, p1796 

    Background. To identify inflammatory pathways that may contribute to the pathogenesis of human immunodeficiency virus (HIV) disease, we explored associations between AIDS or death and different inflammatory markers, including selected soluble tumor necrosis factor superfamily receptors (sTNFRs)...

  • SUMMARY REPORT: TREATING HIV/AIDS. Rabah, Raida // Ethnicity & Disease;Summer2007 Supplement 3, Vol. 17, pS3100 

    The article discusses some advances in treating HIV/AIDS. It is estimated that only eight percent of the four million infected people in Africa are receiving antiretrovirals. Drugs that target different stages and steps in viral replications have been developed and are best used in combinations...

  • Novel Inhibitors of HIV-1 Integration. Witvrouw, M.; Van Maele, B.; Vercammen, J.; Hantson, A.; Engelborghs, Y.; Clercq, E. De; Pannecouque, C.; Debyser, Z. // Current Drug Metabolism;Aug2004, Vol. 5 Issue 4, p291 

    Human immunodeficiency virus (HIV) is the etiological agent of the acquired immune deficiency syndrome (AIDS). The current strategy for the treatment of HIV infection is called Highly Active Antiretroviral Therapy (HAART) and is based on cocktails of drugs that are currently approved by the Food...

  • Long-Term Decay of the HIV-1 Reservoir in HIV-1 -- Infected Children Treated with Highly Active Antiretroviral Therapy. Zanchetta, Marisa; Walker, Sarah; Burighel, Nicoletta; Bellanova, Domenico; Rampon, Osvalda; Giaquinto, Carlo; De Rossi, Anita // Journal of Infectious Diseases;6/15/2006, Vol. 193 Issue 12, p1718 

    To investigate the decay of the human immunodeficiency virus type 1 (HIV-1) reservoir in children receiving highly active antiretroviral therapy (HAART), we measured HIV-1 DNA in peripheral blood mononuclear cells from 14 children who achieved and maintained suppression of plasma viremia up to...

  • New drug for HIV patients.  // MLO: Medical Laboratory Observer;May2007, Vol. 39 Issue 5, p10 

    The article reports on the study conducted by Merck Research Laboratories which reveals the potential of the Raltegravir drug in fighting drug-resistant human immunodeficiency virus (HIV). Raltegravir is one of the new class of drugs called integrase-inhibitors, which blocks an enzyme essential...

  • Raltegravir. Croxtall, Jamie D.; Lyseng-Williamson, Katherine A.; Perry, Caroline M. // Drugs;2008, Vol. 68 Issue 1, p131 

    Raltegravir, the first in a new class of orally administered HIV type-1 (HIV-1) integrase inhibitors, selectively inhibits the strand transfer activity of HIV-1 and its integration into human DNA, a key stage in retroviral propagation, thereby limiting viral replication and the infection of new...

  • Risk of breast, ovary, and uterine corpus cancers among 85,268 women with AIDS. Goedert, J. J.; Schairer, C.; McNeel, T. S.; Hessol, N. A.; Rabkin, C. S.; Engels, E. A.; HIV/AIDS Cancer Match Study // British Journal of Cancer;9/4/2006, Vol. 95 Issue 5, p642 

    By linking HIV/AIDS and cancer surveillance data in 12 US regions, breast and reproductive cancer risks with AIDS were compared to those in the general population. Trends in standardized incidence ratios (SIRs) were assessed by CD4 count, AIDS-relative time, and calendar time. Standardized...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics